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is also important when identifying appropriate therapeutic
options for patients who have progressed on trastuzumab (TZ).
This study explores UK treatment patterns for women with
HER2 + MBC who progress while on TZ, and have been previ-
ously treated with an anthracycline and a taxane (A&T).
METHODS: Case histories from 2815 women with MBC seen
January 2006 to December 2007 were retrieved from the IMS
Advanced Disease Analyzer database: 421 had received TZ in the
metastatic setting. Changes in therapy were used as a proxy for
disease progression; patients receiving TZ monotherapy within
28 days of ending a previous regimen were excluded from this
deﬁnition to ensure that TZ use as a maintenance treatment was
not inappropriately characterised as progression. Therapeutic
regimens received post-progression were characterised for 98
patients who had progressed on TZ. Results were compared with
a UK treatment survey completed by oncologists with a specialist
interest in breast cancer (n = 92). RESULTS: Of the 98 patients
that progressed on TZ, 54 (55.1%) continued receiving a
TZ-containing regimen, most commonly in combination with
capecitabine (n = 21; 21.4%) or vinorelbine (n = 20; 20.4%).
Capecitabine monotherapy was also commonly used (n = 31;
31.6%). Re-challenge with a taxane was uncommon (n = 1;
1.0%). Major regimens received post-progression on TZ, as
identiﬁed from case histories, agreed closely with results from the
treatment survey. CONCLUSIONS: This study demonstrates
that, despite the lack of a robust evidence base in this population,
a high proportion of patients continue to receive a TZ-containing
regimen post-progression. This highlights a clear need for
evidence-based HER2 targeted therapy in a patient population
where effective treatment options are limited.
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OBJECTIVES: The objective of this study was to examine racial
differences in total and prescription related health care costs and
service utilization associated with adjuvant hormonal therapy in
women with primary breast cancer. METHODS: This was a
retrospective cohort study of Medicaid enrollees with hormone
receptor positive breast cancer newly starting adjuvant hor-
monal therapy. The study used North Carolina Medicaid data,
which was linked to the North Carolina Cancer Registry. The
patients were followed for one year after commencing the index
medication (tamoxifen or aromatase inhibitor) to collect the
data on medication utilization, health care costs, hospitalization
and emergency department (ED) visits. RESULTS: In this cohort
of 609 women with primary breast cancer, mean total health
care costs was $14,513.31 (SD = $15,233.17), which did not
differ signiﬁcantly across the racial groups [white = mean (SD)
$15,261.13 ($16,225.15); black = mean (SD) $13,580.61
($13,870.34); p > 0.05]. Overall mean prescription related costs
were $4612.18 (SD = $3509.59) with white patients having a
signiﬁcantly higher costs [mean (SD) = $5000.51 ($3582.29)] as
compared to black patients [mean (SD) = $4127.85 ($3360.83]
(p < 0.05). After controlling for select background variables,
prescription related costs remained signiﬁcantly higher in white
patients [p < 0.05]; however total health care costs did not differ
signiﬁcantly across the racial groups [p > 0.05]. The likelihood
of hospitalization was signiﬁcantly lower by 33% in black
patients as compared to white patients after controlling for select
background variables (p < 0.05). Black race was associated with
a 3% increase in the likelihood of an ED visit; however the
difference was statistically insigniﬁcant (p < 0.05). CONCLU-
SIONS: In this study white patients had lower non-prescription
related costs as a result of lower service utilization. Higher medi-
cation compliance in white patients may drive prescription
related costs upwards but may consequently reduce the total
health care costs.
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OBJECTIVES: Assess the geographical distribution of the
nationally available resources for the diagnosis/treatment of
patients with cancer in Greece, in order to identify disparities in
available capacity between various geographic regions that
impact on the equality of access to effective care. METHODS:
Due to lack of a centralized cancer registry as well as a national
hospital capacity database, there is no record of either cancer
prevalence or hospital capacity to treat cancer per geographic
region. In this light, a questionnaire-based survey was conducted
to all public and private sector hospitals in Greece, in order to
record their capacity to diagnose/treat cancer. Special emphasis
was placed on the recording of oncology clinic beds and chemo-
therapy beds. Data were clustered according to geographical
region (a total of 11 in Greece) and compared to the percentage
of the population in the region, as calculated in the 2001 census.
RESULTS: Major discrepancies were observed in the distribution
of resources in favor of large urban areas. The majority of the
nationally available oncology clinic beds and chemotherapy beds
(61.6% and 56.4% respectively) is located in the district of
Attica, an area where only 32.2% of the total Greek population
resides. Excess clustering above population percentages is
observed in 2 more districts (that include large urban centers, as
well), whereas for 3 districts, mainly rural, accounting in total for
16,3% of the country population, no available beds were
recorded CONCLUSIONS: Clustering of oncology speciﬁc
resources exceeds the spatial concentration pattern of health care
services observed in Greece. Geographical misdistribution is a
major contributor to access inequalities in health. Fair allocation
of resources according to population distribution could contrib-
ute to achieving earlier access to effective health care, thus reduc-
ing the burden of the disease, lowering the cost for seeking
adequate treatment for the household and ensuring equality in
access.
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OBJECTIVES: The Slovak health care system is funded on the
principles of solidarity, non-proﬁtability and plurality in a
system of compulsory health insurance. Slovakia’s GDP is cur-
rently 58% of the EU 15 GDP average, but is forecasted to
reach 80% of the EU 15 GDP average by 2025. A person born
in Slovakia in 2002 can expect to live 73.9 years on average.
Leading disability causes as % of DALY in Slovakia (2002) in
total DALYs for men with malignant neoplasms were 14.4%
and for women 13.5%. METHODS: We have analysed the
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access and uptake of novel oncology drugs in the Slovak repub-
lic over a 7 year period based on sales data provided by IMS
Health. Slovakia has a national public oncology register, which
collects incidence, mortality and stage of diagnosis on all cancer
types. We linked the national cancer epidemiological data to
the cancer drug list and to the sales for cancer drugs. We per-
formed analysis of the possible effect of novel cancer drug
introduction and consumption on cancer survival and mortal-
ity. RESULTS: Oncological disease mortality in Slovakia had an
increasing trend on a long-term basis, from 1999–2000 the
mortality has decreased. Incidence and prevalence (in accor-
dance with the world trends) increases. According to IMS and
OECD health data the market for L01 and L02 drugs was
€53,593 000, this represents €10 per inhabitant. Expenditures
in L01 + L02 accounts for 8,9% of the Rx expenditures or
7,9% of Total Pharma Market. CONCLUSIONS: Patient
access to new cancer drugs in Slovakia improved signiﬁcantly in
the last years. It is highly probable that the improving survival
is related to the use of modern surgical and diagnostic methods,
earlier diagnostics of oncological diseases and better availability
of innovative drugs.
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OBJECTIVES: Public health approaches for prevention are con-
sidered to be successful with climbs in the numbers of services
rendered. However, more thorough evaluations are required to
uncover the still unmet need that remains hidden and harder to
reach. The objective of this study is to estimate the impact of
physician supply, mammography facilities, and managed care
penetration on use of mammography screening. METHODS:
Retrospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System for years 2000, 2002, and 2004
along with county level supply variables from area resource ﬁle,
were used in the analysis. The analysis was restricted to females
between 40–69 years of age. We estimate a series of multivariate
regression model to assess the effect of individual and contextual
supply variables on mammography screening. We also use varia-
tion in the physician supply, managed care penetration at the
county level over the 5-year period to estimate its impact on
mammography screening using a ﬁxed effect estimation
approach. RESULTS: Women living in rural areas were less likely
(Coefﬁcient = -0.023, 95% CI = -0.031–0.014) to obtain a
mammogram even after controlling for supply side variable .
Among the supply side variables only managed care penetration
signiﬁcantly predicted mammography screening. In areas with
higher managed care penetration, women were more likely to get
screened. CONCLUSIONS: Insurance status was one of the
major determinants of mammography screening for females
residing in rural areas. Contextual supply variables had lesser
impact on mammography screening compared to individual level
characteristics.
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OBJECTIVES: To evaluatie simultaneously frequency of occur-
rence, outcomes, and cost of care of renal cell carcinoma (RCC),
in order to provide empiric evidence on the burden of RCC.
METHODS: Retrospective, naturalistic longitudinal study based
on claims of individuals enrolled in the Friuli Venezia Giulia
(FVG) administrative database. Since 1980, all FVG inhabitants
are registered in an administrative database which includes infor-
mation on hospital admissions, outpatients care, pharmaceutical
prescriptions and mortality. We selected residents of FVG who
had a RCC ﬁrst hospital admission (ICD9 code 189) during the
period 2000–2004, and we followed them up until: June 30,
2005, death or transfers. Direct medical costs (hospitalizations,
drugs, visits, diagnostics and laboratory exams) were quantiﬁed
using prices or tariffs expressed in Euro 2005. The perspective of
FVG Regional Health Service was adopted. Survival and costs
analysis were performed considering the presence or the absence
of metastases. RESULTS: We enrolled 1358 patients (63% male),
the 18.8% representing a metastatic-stage, leading to a crude
incidence of 23/100,000 person-years. During follow-up, 76% of
the metastatic patients and 21% of the non metastatic patients
died. The risk of death was signiﬁcantly higher among metastatic
stage patients with a median survival of about six months. The
cost per patient related to the ﬁrst year after diagnosis for sub-
jects with and without metastases was €13,692 and 10,502 Euro,
respectively, with a mean difference of 3,363 Euro after adjusting
for age and sex. Total health care costs per-patient over the
maximum of follow-up were €16,090 for the localized-stage
group and €17,656 in the metastatic-stage group. CONCLU-
SIONS: Results from our study show that, due to the large
number of hospitalizations and the high mortality, the epidemio-
logic and socioeconomic burden to the health care system and to
the society of RCC is high.
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OBJECTIVES: In order for a new pharmaceutical treatment to
demonstrate cost-effectiveness, it is important to understand the
current standard clinical management practices for the relevant
patient population. In some therapeutic areas, this information
can be readily gleaned from clinical practice guidelines, data-
base analyses and clinical input. However, in more complex
conditions, standard practices are undeﬁned and vary markedly
both within and between countries. In such circumstances,
valuable information can be obtained by conducting a chart
audit. We report on the different approaches and requirements
for conducting chart audits in Australian hospitals.
METHODS: In total, 79 potential investigators were invited to
participate in two separate studies. Investigators were contacted
up to four times to maximise response. 52 investigators
responded and 12 agreed to participate. Two investigators
agreed to participate in both studies. RESULTS: All sites
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